Cynata Therapeutics Limited
CYYNF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $1,885 | $2,316 | $1,654 | $7,770 |
| % Growth | -18.6% | 40% | -78.7% | – |
| Cost of Goods Sold | $0 | $281 | $280 | $280 |
| Gross Profit | $1,885 | $2,035 | $1,374 | $7,490 |
| % Margin | 100% | 87.9% | 83.1% | 96.4% |
| R&D Expenses | $7,681 | $8,962 | $12,674 | $9,105 |
| G&A Expenses | $0 | $0 | $3,176 | $3,994 |
| SG&A Expenses | $2,328 | $2,161 | $3,232 | $4,060 |
| Sales & Mktg Exp. | $0 | $0 | $56 | $66 |
| Other Operating Expenses | $0 | $0 | $356 | -$1,107 |
| Operating Expenses | $10,009 | $11,124 | $16,263 | $12,058 |
| Operating Income | -$8,124 | -$8,808 | -$13,000 | -$4,287 |
| % Margin | -430.9% | -380.4% | -785.8% | -55.2% |
| Other Income/Exp. Net | -$1,267 | -$3,252 | -$1,278 | -$1,158 |
| Pre-Tax Income | -$9,391 | -$12,060 | -$14,277 | -$5,445 |
| Tax Expense | $0 | -$2,316 | $0 | $0 |
| Net Income | -$9,391 | -$9,745 | -$14,277 | -$5,445 |
| % Margin | -498.1% | -420.8% | -863% | -70.1% |
| EPS | -0.046 | -0.054 | -0.098 | -0.038 |
| % Growth | 15.5% | 44.9% | -158.9% | – |
| EPS Diluted | -0.046 | -0.054 | -0.098 | -0.038 |
| Weighted Avg Shares Out | 204,954 | 179,633 | 145,092 | 143,277 |
| Weighted Avg Shares Out Dil | 204,951 | 179,632 | 145,092 | 143,277 |
| Supplemental Information | – | – | – | – |
| Interest Income | $228 | $418 | $353 | $65 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $283 | $280 | $280 | $280 |
| EBITDA | -$9,328 | -$9,950 | -$16,263 | -$13,558 |
| % Margin | -494.8% | -429.7% | -983% | -174.5% |